Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.

Dietary supplement marketers making claims of helping alleviate symptoms of withdrawal from drug abuse were warned, an advocacy group that asked federal agencies to investigate was thanked and some of the targeted products remain available for sale.

FDA and the Federal Trade Commission on Jan. 24 announced joint warning letters submitted earlier in the month to 11...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America